Real‐world utilization of EGFR TKIs and prognostic factors for survival in EGFR‐mutated non‐small cell lung cancer patients with brain metastases

Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR)‐mutated NSCLC with BM is debatable. We aimed to investigate the impact of different treatments among patients with EGFR‐mutated NSCLC. A cohort of 2058 lung cancer patients with BM between 2013 and 2018 was retrospectively studied. A total of 571 patients with EGFR‐mutated...